Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

600196 Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.

Closed 12-19 15:00:00

27.27

+0.59

+2.21%

High27.45	Low26.68	Vol18.69M
Open26.79	D1 Closing26.68	Amplitude2.89%
Mkt Cap72.81B	Tradable Cap57.76B	Total Shares2.67B
T/O509.00M	T/O Rate0.88%	Tradable Shares2.12B
P/B1.52	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.","latestPrice":27.27,"timestamp":1766127600000,"preClose":26.68,"halted":0,"volume":18686250,"delay":0,"changeRate":0.0221,"floatShares":2118000000,"shares":2670000000,"eps":1.2293,"marketStatus":"Closed","change":0.59,"latestTime":"12-19 15:00:00","open":26.79,"high":27.45,"low":26.68,"amount":509000000,"amplitude":0.0289,"askPrice":27.27,"askSize":770,"bidPrice":27.26,"bidSize":239,"shortable":0,"etf":0,"ttmEps":1.2293,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766367000000},"marketStatusCode":5,"adr":0,"adjPreClose":26.68,"symbolType":"stock","openAndCloseTimeList":[[1766107800000,1766115000000],[1766120400000,1766127600000]],"highLimit":29.35,"lowLimit":24.01,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2670429325,"isCdr":false,"pbRate":1.52,"roa":"--","peRate":22.183356,"roe":"5.3%","epsLYR":1.04,"committee":-0.387057,"marketValue":72823000000,"turnoverRate":0.0088,"status":0,"hkstockBrief":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"FOSUN PHARMA","latestPrice":21.08,"timestamp":1766131686005,"preClose":20.62,"halted":0,"volume":4570108,"delay":0,"premium":"-30.10"},"floatMarketCap":57771000000},"requestUrl":"/m/hq/s/600196/tweets","defaultTab":"tweets","newsList":[{"id":"2592324301","title":"Fosun Pharma, ClavisBio Sign Five-Year Drug Collaboration Agreement; Shanghai Shares Rise 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592324301","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592324301?lang=en_us&edition=fundamental","pubTime":"2025-12-19 11:57","pubTimestamp":1766116658,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  subsidiary Fosun Pharma Industry and  ClavisBio signed a five-year drug collaboration agreement, according to a Friday filing with the Shanghai bourse.The two companies will promote the preclinical development of the drugs.ClavisBio will have the option to exclusively license the development, production, and commercialization of the products worldwide except in mainland China, Hong Kong, and Macau, where Fosun will have rights.Should ClavisBio exercise its right to the projects, Fosun will be eligible for up to $362.5 million for a single project.Fosun will also be entitled to royalties and a predetermined minority stake in a new project company set up by ClavisBio controlling shareholder AditumBioFund3 for the project, the filing said.Shares in Fosun Pharma rose 3% in Shanghai and 2% in Hong Kong during late morning trading on Friday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0096","BK0060","BK0188","BK1191","BK1515","02196","BK0239","BK0175","BK0012","BK0183","BK0187","BK0028","BK1593","BK0196","600196"],"gpt_icon":0},{"id":"1160431538","title":"Fosun United Health Insurance Withdraws Announcement of 9 Medical Insurance Plans Covering Innovative Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=1160431538","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160431538?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:21","pubTimestamp":1766064115,"startTime":"0","endTime":"0","summary":"Days after the first edition of the \"Commercial Health Insurance Innovative Drug Catalog\" was released, listing 19 innovative drugs for commercial health insurance coverage, the industry eagerly...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1119994496.HKD","LU2347655156.SGD","SG9999017495.SGD","SG9999014898.SGD","LU0048584097.USD","LU1791710400.SGD","IE00B19Z3B42.SGD","LU1670628061.USD","LU1061106388.HKD","600196","LU1037948541.HKD","LU0976567544.SGD","LU2271345857.HKD","BK4581","IE00BZ1G4Q59.USD","IE00BFSS7M15.SGD","IE000M9KFDE8.USD","LU0795875169.SGD","LU0708995401.HKD","IE00B19Z9Z06.USD","LU1066051498.USD","IE00B7KXQ091.USD","LU2023251221.USD","LU2360032135.SGD","LU2461242641.AUD","02196","LU0198837287.USD","LU0211326839.USD","IE0004445239.USD","LU0861579265.USD","LU2236285917.USD","LU0820561909.HKD","LU0545039389.USD","LU2125154935.USD","LU1718418525.SGD","LU1732800096.USD","IE00BWXC8680.SGD","LU2244417387.USD","LU0052756011.USD","LU1548497426.USD","BK4533","IE0004445015.USD","LU2361045086.USD","BK4588","SG9999014914.USD","LU0496365809.HKD","LU0417517546.SGD","LU0109391861.USD","LU0029864427.USD","IE00B19Z8X17.USD","LU0094547139.USD","LU0557290698.USD","LU1854104046.USD","IE0002141913.USD","LU1720051017.SGD","LU1778281490.HKD","LU1064131342.USD","LU2242649171.HKD","SGXZ31699556.SGD","IE00B775H168.HKD","LU1037948897.HKD","LU2362540622.SGD","IE00BFTCPJ56.SGD","LU0053666078.USD","LU0128525929.USD","LU0238689110.USD","LU2028103732.USD","LU2089984988.USD","IE00BJJMRY28.SGD","LU2491050071.SGD","SG9999002224.SGD","LU1267930490.SGD","IE00BKPKM429.USD","LU1983299246.USD","IE00B2B36J28.USD","BK4534","IE0002270589.USD","LU1791710582.SGD","LU1291159041.SGD","LU0882574055.USD","SG9999001176.USD","LU0310800965.SGD","SG9999002232.USD","LU0320765059.SGD","LU0107464264.USD","LU1074936037.SGD","LU0820561818.USD","LU0965509283.SGD","LU2125154778.USD","LU0708994859.HKD","LU2133065610.SGD","LU0211328371.USD","IE00BZ9MQY76.HKD","IE00B19Z9505.USD","IE00BJJMRX11.SGD","IE0005OL40V9.USD","LU1496350502.SGD","LU2552382058.USD","LU0097036916.USD","IE00BN29S564.USD","LU2089284900.SGD","LU0234572021.USD","LU0251132253.USD","SG9999013999.USD","LU1069347547.HKD","IE0009355771.USD","LU0011850046.USD","LU0211327993.USD","LU0211326755.USD","LU0266013472.USD","LU0122379950.USD","LU0553294199.USD","LU1066051225.USD","LU1670627923.USD","LU0203347892.USD","LU0310800379.SGD","LU2211815571.USD","LU1023059063.AUD","IE00BFXG1179.USD","LU0528227936.USD","LU0354030511.USD","LU1267930730.SGD","LU2361044865.SGD","LU1066051811.HKD","LU1674673428.USD","LU2362541513.USD","LU1267930227.SGD","LU0683600562.USD","LU1814569148.SGD","LU1066053197.SGD","LU0661504455.SGD","BK1574","LU0353189680.USD","SG9999018865.SGD","IE00BFSS8Q28.SGD","LU0949170772.SGD","IE00B19Z9P08.USD","LU0689472784.USD","LU0738911758.USD","IE00BKVL7J92.USD","LU1267930573.SGD","LU0965508806.USD","BK1161","LU0256863811.USD","SG9999018857.SGD","LU0058720904.USD","LU1854103824.USD","LU2357305700.SGD","LU1057294990.SGD","SG9999001176.SGD","SG9999014906.USD","SGXZ57979304.SGD","LU1551013342.USD","LU1084165304.USD","LU2552382215.SGD","LU0354030438.USD","LU0077335932.USD","IE00BSNM7G36.USD","LU0820562030.AUD","LU0345770993.USD","LU2087625088.SGD","LU0114720955.EUR","LU0823416689.USD","LU2089283258.USD","BK4585","BK4532","IE00B4JS1V06.HKD","SGXZ81514606.USD","LU0345770308.USD","LU2491049909.HKD","LU0149725797.USD","IE00B19Z8W00.USD","LU0456855351.SGD","LU1674673691.USD","SGXZ51526630.SGD","LU0158827781.USD","LU0310799852.SGD","LU1261432733.SGD","LU2111349929.HKD","LU0342679015.USD","LU2362541273.HKD","LU0289739699.SGD","LU0912757837.SGD","LU1003077747.HKD","LU2264538146.SGD","IE00B1XK9C88.USD","IE00BJJMRZ35.SGD","IE00B19Z3581.USD","LU1934455277.USD","LU0672654240.SGD","IE00B7SZLL34.SGD","LU0787776722.HKD","LU1988902786.USD","IE00BJT1NW94.SGD","LU2112291526.USD","LU1934455194.USD","LU1506573853.SGD","LU0079474960.USD","LU1323610961.USD","LU1934455863.HKD","IE00B894F039.SGD","LU2491050154.USD","LU0965509010.AUD","LU0158827948.USD","LU0353189763.USD","LU0965509101.SGD","LU1914381329.SGD","SG9999014880.SGD","LU2324357040.USD","LU0432979614.USD","LU1153585028.USD","BK4154","LU2552382132.HKD","LU1732799900.SGD","LU1551013425.SGD","LU2279689827.SGD","BK4566","SGXZ99366536.SGD","LU0128525689.USD","IE00B1BXHZ80.USD","IE00B4R5TH58.HKD","LU0795875086.SGD","LU0943347566.SGD","LU0203345920.USD","LU0316494557.USD","LU0187121727.USD","LU1035773651.USD","LU2468319806.SGD","LU1720051108.HKD","LU1989771016.USD","LU2361044949.HKD"],"gpt_icon":0},{"id":"2592972480","title":"BRIEF-Fosun Pharma's Unit Signs Co-Development, Licensing Options Deal With Clavis Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2592972480","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592972480?lang=en_us&edition=fundamental","pubTime":"2025-12-18 18:33","pubTimestamp":1766053985,"startTime":"0","endTime":"0","summary":"BRIEF-Fosun Pharma's Unit Signs Co-Development, Licensing Options Deal With Clavis Bio Dec 18  - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:SAYS UNIT SIGNS DEAL WITH CLAVIS BIO FOR CO-DEVELOPMENT AND EXCLUSIVE LICENSING OPTIONSSAYS COULD RECEIVE UP TO $362.5 MILLION PER PROJECT IF CLAVIS BIO EXERCISES OPTIONSource textFurther company coverage: 600196.SS  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nL4N3XO0QP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","BK0012","BK0060","BK0096","BK0028","BK0175","BK0187","BK0196","600196","BK0188","BK0239"],"gpt_icon":0},{"id":"2592897215","title":"Fosun Pharmaceutical Says Could Receive up to $362.5 Mln per Project IF Clavis Bio Exercises Option","url":"https://stock-news.laohu8.com/highlight/detail?id=2592897215","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592897215?lang=en_us&edition=fundamental","pubTime":"2025-12-18 18:33","pubTimestamp":1766053985,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nL4N3XO0QP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0175","BK0188","BK0060","BK0096","600196","BK0183","BK0028","BK0187","BK0239","BK0196","BK0012"],"gpt_icon":0},{"id":"2592972155","title":"Fosun Pharmaceutical  Says Unit Signs Deal With Clavis Bio for Co-Development and Exclusive Licensing Options","url":"https://stock-news.laohu8.com/highlight/detail?id=2592972155","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592972155?lang=en_us&edition=fundamental","pubTime":"2025-12-18 18:33","pubTimestamp":1766053984,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nL4N3XO0QP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0188","BK0096","BK0239","BK0060","BK0183","BK0175","BK0012","600196","BK0187","BK0028","BK0196"],"gpt_icon":0},{"id":"1115920738","title":"FOSUN PHARMA (600196.SH) Subsidiary Signs Collaboration and Option Agreement with Clavis Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=1115920738","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115920738?lang=en_us&edition=fundamental","pubTime":"2025-12-18 18:32","pubTimestamp":1766053961,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA (600196.SH) announced that on December 18, 2025, its subsidiary Fosun Pharma Industrial entered into a Collaboration and Option Agreement with Clavis Bio. Under the agreement, during the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0188","02196","BK1593","BK0096","BK1515","BK0187","BK1191","BK0196","BK0175","BK0012","BK0239","BK0183","600196","BK0060"],"gpt_icon":0},{"id":"1183029810","title":"Fosun Pharma Acquires Green Valley Pharma: A Ray of Hope for Alzheimer's Patients?","url":"https://stock-news.laohu8.com/highlight/detail?id=1183029810","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183029810?lang=en_us&edition=fundamental","pubTime":"2025-12-16 17:00","pubTimestamp":1765875658,"startTime":"0","endTime":"0","summary":"In the pharmaceutical industry, a drug once hailed as a beacon of hope for domestic innovation—yet mired in scientific controversy—awaits redemption. On December 15, Fosun Pharma announced its...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK0096","BK0060","BK0012","BK1574","600196","02196","BK0187","BK0239","BK1593","159938","09939","BK0188","BK1161","BK0175","BK0028","BK0196","BK0183","BK1515"],"gpt_icon":0},{"id":"2591862118","title":"BUZZ-Pfizer shares up ahead of co analyst and investor call Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2591862118","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591862118?lang=en_us&edition=fundamental","pubTime":"2025-12-16 04:52","pubTimestamp":1765831962,"startTime":"0","endTime":"0","summary":"** Shares of Pfizer PFE.N are up 2.9% on Mon ahead of the co's analyst and investor. ** Analysts expecting Q1 2026 EPS of 77 cents and FY 2026 EPS of $3.05, per LSEG data","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL6N3XL12A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225771236.USD","LU0234572021.USD","LU0321505439.SGD","600196","SG9999011175.SGD","LU0058720904.USD","SG9999003800.SGD","IE000M9KFDE8.USD","LU1066053197.SGD","LU1883839398.USD","BK0196","BK0239","LU0122379950.USD","LU0456855351.SGD","LU1894683264.USD","LU0170899867.USD","BK4007","BK0028","BK4568","IE0002270589.USD","SG9999013999.USD","LU0321505868.SGD","SG9999002224.SGD","LU1894683348.USD","IE00B19Z3B42.SGD","BK4592","BK0187","LU0289739699.SGD","LU0306806265.USD","LU1023059063.AUD","SG9999001176.SGD","IE00B19Z3581.USD","SG9999002232.USD","IE00BBT3K403.USD","BK4585","BK0060","BK0012","BK4534","PFE","SG9999001176.USD","LU1066051498.USD","00656","IE00BLSP4452.SGD","LU0225284248.USD","BK4599","BK4588","BK4581","BK0188","BK0096","BK1230"],"gpt_icon":1},{"id":"2591422006","title":"Fosun Pharma to Acquire Majority Stake in Alzheimer's Drug Developer for RMB1.27 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2591422006","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591422006?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:38","pubTimestamp":1765809515,"startTime":"0","endTime":"0","summary":"Fosun Pharma Industrial has entered into an agreement to acquire 8.6667% equity interest in a target company from Shiyin Investment and Shibirun for a total consideration of RMB143 million. Following the transaction, Fosun Pharma Industrial will also subscribe for newly increased registered capital in the target company, investing RMB1,269 million to secure a 46.3504% equity stake after completion. In addition, Fosun Pharma Industrial and the founder of the target company or their affiliates will jointly establish a special purpose vehicle , with Fosun Pharma Industrial holding a 51% stake and the founder or affiliates holding 49%. The SPV will acquire a 2% equity interest in the target company from Shanghai Yaoqijiu for RMB1 or the minimum legally permissible price. The transaction aims to strengthen Fosun Pharma Group's position in the market and advance clinical development for Alzheimer's disease treatments.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL736gGY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0096","BK0028","BK0012","BK0196","BK1230","BK0060","00656","BK0188","BK0183","BK0187","600196","BK0239","BK0175"],"gpt_icon":0},{"id":"2591614090","title":"Shanghai Fosun Pharmaceutical  Says Unit Plans to Invest Total of 1.4 Bln Yuan to Acquire Controlling Stake in Pharmaceutical Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2591614090","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591614090?lang=en_us&edition=fundamental","pubTime":"2025-12-15 17:38","pubTimestamp":1765791500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL4N3XL0LN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0188","BK0239","BK0183","BK0028","BK0196","BK0096","BK0012","BK0175","BK0060","BK0187","600196"],"gpt_icon":0},{"id":"2591612345","title":"BRIEF-Shanghai Fosun Pharmaceutical's Unit Plans To Acquire Controlling Stake In Pharmaceutical Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2591612345","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591612345?lang=en_us&edition=fundamental","pubTime":"2025-12-15 17:38","pubTimestamp":1765791500,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Fosun Pharmaceutical's Unit Plans To Acquire Controlling Stake In Pharmaceutical FirmDec 15  - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:SAYS UNIT PLANS TO INVEST TOTAL OF 1.4 BILLION YUAN  TO ACQUIRE CONTROLLING STAKE IN PHARMACEUTICAL FIRMSource textFurther company coverage: 600196.SS  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL4N3XL0LN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0028","600196","BK0239","BK0175","BK0012","BK0187","BK0060","BK0196","BK0096","BK0183"],"gpt_icon":0},{"id":"2591613958","title":"Fosun Pharma Seeks Approval for New Indication of Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2591613958","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591613958?lang=en_us&edition=fundamental","pubTime":"2025-12-15 15:14","pubTimestamp":1765782895,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  said China's drug regulator accepted subsidiary Henlius' new drug registration application for serplulimab injection for a new additional indication.The indication is in combination with platinum-based chemotherapy as neoadjuvant and postoperative adjuvant therapy for PD-L1-positive, resectable gastric cancer patients, according to a Dec. 12 filing with the Shanghai bourse.Shares of the pharmaceutical company were down 1% in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK0060","BK0239","BK0175","BK0183","600196","BK0196","BK0012","BK0187","BK0028","BK0096"],"gpt_icon":0},{"id":"2591074618","title":"Fosun Pharma Gets Clinical Trial Approval for Topical Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2591074618","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591074618?lang=en_us&edition=fundamental","pubTime":"2025-12-15 15:02","pubTimestamp":1765782178,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  subsidiary Zhaohui Pharmaceutical received the approval from China's drug administrator to start phase three clinical trials for ketoprofen plaster.The topical drug is intended for pain and inflammation related to conditions such as osteoarthritis, lower back pain and tendonitis, according to a Dec. 12 filing with the Shanghai bourse.Shares of the pharmaceutical company were down 1% in recent trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK0060","BK0187","BK0096","BK0028","BK0012","BK0196","BK0239","BK0175","600196","BK0183"],"gpt_icon":0},{"id":"2590505982","title":"FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up","url":"https://stock-news.laohu8.com/highlight/detail?id=2590505982","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590505982?lang=en_us&edition=fundamental","pubTime":"2025-12-12 20:04","pubTimestamp":1765541041,"startTime":"0","endTime":"0","summary":"FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats upChanges dateline, adds new details in paragraph 19, 20, 27, 36 and 54. The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently dominated by Novo Nordisk NOVOb.CO and Eli Lilly LLY.N.Analysts project the industry could rake in $150 billion in annual sales by the next decade.Soaring demand for its obesity treatment has helped Lilly become the first pharmaceutical company to reach","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nL4N3XI0R0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002224.SGD","LU0964806797.USD","LLY","LU1003077747.HKD","LU1989771016.USD","IE0005OL40V9.USD","BK0028","LU1989772840.SGD","SRRK","LU0130517989.USD","MRK","LU0345777147.USD","LU1061106388.HKD","IE00BJJMRX11.SGD","IE00BN8TJ469.HKD","LU0306806265.USD","IE00BJLML261.HKD","LU0211328371.USD","IE00B4JS1V06.HKD","LU0256863902.USD","LU1323610961.USD","SG9999015986.USD","LU0823434583.USD","03933","600196","03165","BK0188","AMGN","SG9999013999.USD","LU0499090636.EUR","LU1720051017.SGD","LU1035775433.USD","ALT","BK0187","SG9999014906.USD","02105","00656","03692","GPCR","LU0106261372.USD","OPK","IE0002141913.USD","VKTX","MTSR","AZN.UK","BK4566","LU2106854487.HKD","SGXZ99366536.SGD","IE00BK4W5M84.HKD"],"gpt_icon":1},{"id":"2590039835","title":"Shanghai Fosun Pharma - Received Approval From China's Nmpa for Clinical Trial of Unit's Ketoprofen Patch","url":"https://stock-news.laohu8.com/highlight/detail?id=2590039835","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590039835?lang=en_us&edition=fundamental","pubTime":"2025-12-12 19:36","pubTimestamp":1765539409,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nFWN3XI0P3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0028","BK0188","BK0183","BK0060","BK0239","BK0187","BK0012","600196","BK0096","BK0175","BK0196"],"gpt_icon":0},{"id":"2590503933","title":"Shanghai Fosun Pharmaceutical Subsidiary Wins Approval for Ketoprofen Patch Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2590503933","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590503933?lang=en_us&edition=fundamental","pubTime":"2025-12-12 19:36","pubTimestamp":1765539382,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical Subsidiary Zhaohui Pharma Receives Approval for Ketoprofen Patch Phase III Clinical Trial. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 12, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDLc6cwnx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","00656","BK0239","600196","BK0188","BK0028","BK0187","BK0183","BK0196","BK1230","BK0060","BK0012","BK0096"],"gpt_icon":0},{"id":"1131221386","title":"FOSUN PHARMA (600196.SH): Supplemental New Drug Application for Serplulimab Injection Accepted","url":"https://stock-news.laohu8.com/highlight/detail?id=1131221386","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131221386?lang=en_us&edition=fundamental","pubTime":"2025-12-12 17:46","pubTimestamp":1765532781,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA (600196.SH) announced that its subsidiary Shanghai Henlius Biotech, Inc. and its controlled subsidiaries recently had the supplemental new drug application for Serplulimab Injection...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK0096","BK0188","02196","BK0028","BK0060","BK1191","BK0183","BK0196","600196","BK0175","BK0187","BK1515","BK0239","BK0012"],"gpt_icon":0},{"id":"1141587831","title":"FOSUN PHARMA (600196.SH): Ketoprofen Patch Receives Clinical Trial Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1141587831","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141587831?lang=en_us&edition=fundamental","pubTime":"2025-12-12 17:40","pubTimestamp":1765532424,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA (600196.SH) announced that its subsidiary, Shanghai Zhaohui Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration to conduct clinical trials...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK0175","BK0012","BK1515","BK0188","BK0239","600196","BK0060","BK0028","BK1593","02196","BK0196","BK0183","BK0096","BK0187"],"gpt_icon":0},{"id":"2590981585","title":"BRIEF-Shanghai Fosun Pharma Says Foscarnet Sodium Injection Of Unit Approved By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2590981585","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590981585?lang=en_us&edition=fundamental","pubTime":"2025-12-10 18:20","pubTimestamp":1765362046,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Fosun Pharma Says Foscarnet Sodium Injection Of Unit Approved By NMPADec 10 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:FOSCARNET SODIUM INJECTION OF UNIT APPROVED BY NMPAFurther company coverage: 600196.SS ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nFWN3XG04A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0012","BK0239","BK0060","BK0183","BK0196","BK0187","BK0028","BK0096","BK0175","600196"],"gpt_icon":0},{"id":"2590600585","title":"Shanghai Fosun Pharma -  Foscarnet Sodium Injection of Unit Approved by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2590600585","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590600585?lang=en_us&edition=fundamental","pubTime":"2025-12-10 18:19","pubTimestamp":1765361990,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nFWN3XG04A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0183","BK0188","BK0196","BK0187","BK0060","600196","BK0175","BK0012","BK0096","BK0028","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1998-08-07","address":"上海市普陀区曹杨路510号9楼","stockEarnings":[{"period":"1week","weight":-0.0652},{"period":"1month","weight":-0.0458},{"period":"3month","weight":-0.1374},{"period":"6month","weight":0.1052},{"period":"1year","weight":0.0397},{"period":"ytd","weight":0.0861}],"companyName":"上海复星医药(集团)股份有限公司","boardCode":"AI0027","perCapita":"--","boardName":"医药制造业","registeredCapital":"267042万元","compareEarnings":[{"period":"1week","weight":0.0008},{"period":"1month","weight":-0.0161},{"period":"3month","weight":0.0147},{"period":"6month","weight":0.1537},{"period":"1year","weight":0.1461},{"period":"ytd","weight":0.1565}],"survey":"　　上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是抗肿瘤及免疫调节核心产品、抗感染核心产品、代谢及消化系统核心产品、心血管系统核心产品、中枢神经系统核心产品、原料药和中间体核心产品。","serverTime":1766144343567,"listedPrice":7.15,"stockholders":"0人","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.,600196,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票老虎,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票老虎国际,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.行情,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票行情,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股价,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股市,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票价格,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票交易,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票购买,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction